Premature Ejaculation - Pipeline Review, Q4 2010

Description: Premature Ejaculation - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Premature Ejaculation Pipeline Review, Q4 2010”, provides an overview of the Premature Ejaculation therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. “Premature Ejaculation-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Premature Ejaculation.
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Premature Ejaculation pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Premature Ejaculation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Ejaculation Overview
Therapeutics Development
An Overview of Pipeline Products for Premature Ejaculation
Premature Ejaculation Therapeutics under Development by Companies
Premature Ejaculation Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Premature Ejaculation Therapeutics Development
Shionogi & Co., Ltd.
GlaxoSmithKline plc
Vectura Group plc
Dong-A Pharmaceutical Co., Ltd.
NeuroHealing Pharmaceuticals Inc.
Universities/Institutes Involved in Premature Ejaculation Therapeutics Development
Premature Ejaculation Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Paroxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD502 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Premature Ejaculation - Featured News
Jul 01, 2010: Furiex Receives US Patent For Dapoxetine Method Of Treatment
Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting
Mar 12, 2010: PRILIGY - New approved medication for Premature Ejaculation available for New Zealand
Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA)
Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program
Jun 10, 2009: PPD Confirms Johnson & Johnson Pharmaceutical Research & Development's Completion of Additional Phase III Studies Providing Expanded Safety and Efficacy Data for Priligy Priligy now approved in seven European countries, with filings currently under review in four geographic regions
Apr 13, 2009: NeuroHealing Announces To Present Data On NH02D, Premature Ejaculation Drug At AUA Meeting
Feb 10, 2009: PPD to Receive Milestone Payments for First Regulatory Approvals of Priligy (Dapoxetine) in Finland and Sweden for Treatment of Premature Ejaculation
Feb 10, 2009: Priligy (dapoxetine) receives first regulatory approvals for the treatment of premature ejaculation (PE) in Finland and Sweden
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1464232/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Premature Ejaculation - Pipeline Review, Q4 2010
- **Web Address:** [http://www.researchandmarkets.com/reports/1464232/](http://www.researchandmarkets.com/reports/1464232/)
- **Office Code:** SCD2SI94

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World